<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan R Strosberg, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kenneth K Tanabe, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Whitcomb, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Well-differentiated neuroendocrine tumors (NETs) most commonly originate in the gastrointestinal tract and lung and rarely arise in the genitourinary tract. The term "carcinoid" is still used to describe these tumors; however, preferred terms include NET or neuroendocrine neoplasm (NEN). Well-differentiated NETs that arise in the pancreas, while histologically similar to those arising in the tubular portion of the gastrointestinal tract, are not referred to as "carcinoids" but instead as pancreatic NETs (older term: islet cell tumors). (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Pathology, tumor classification, and nomenclature'</a>.)</p><p>"Carcinoid syndrome" is the term applied to a constellation of symptoms mediated by various humoral factors that are elaborated by some well-differentiated NETs arising in the gastrointestinal tract  (<a class="graphic graphic_table graphicRef79329" href="/d/graphic/79329.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. Typical carcinoid syndrome, consisting primarily of flushing and diarrhea  (<a class="graphic graphic_table graphicRef63079" href="/d/graphic/63079.html" rel="external">table 2</a>), occurs predominantly in patients with metastatic NETs originating in the small intestine. Carcinoid syndrome is rare with lung or genitourinary well-differentiated NETs. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p>Well-differentiated NETs are rare overall, but their age-adjusted incidence in the United States has increased significantly, partly due to increased detection on radiographic imaging and endoscopy.</p><p>This topic will cover the epidemiology, classification, and clinical features of primary well-differentiated NETs (carcinoid tumors) arising in the gastrointestinal and genitourinary systems. The pathology and nomenclature of digestive tract NETs; clinical features and diagnosis of carcinoid syndrome; issues related to tumor localization in well-differentiated NETs arising in the gastrointestinal tract; features and management of high-grade gastroenteropancreatic neuroendocrine carcinoma, bronchial NETs, and thymic NETs; and the management of patients with non-metastatic and metastatic well-differentiated NETs arising in the gastrointestinal tract are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2622.html" rel="external">"Diagnosis of carcinoid syndrome and tumor localization"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16667.html" rel="external">"Thymic neuroendocrine (carcinoid) tumors"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Well-differentiated NETs are relatively rare tumors. In a series of 35,618 NETs (which included pancreatic NETs as well as gastrointestinal NETs [GINETs] at all sites) reported to the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI), the age-adjusted incidence for nonpancreatic primaries was 4.7 per 100,000 [<a href="#rid2">2</a>]. The annual incidence rate for African Americans was higher than for White Americans (6.46 versus 4.6 per 100,000), and the incidence for males was slightly higher than for females (4.97 versus 4.49 per 100,000). The median age at diagnosis for all patients with NETs was 63 years.</p><p>Roughly similar incidence rates were found in a database study from a Swedish registry that focused on 5184 GINETs tumors seen between 1958 and 1998 [<a href="#rid3">3</a>]. Incidence rates for males and females were 2.0 and 2.4 per 100,000, respectively. Although clear risk factors have not been identified, a regression analysis of this database suggested that risk was increased in the setting of a family history of a GINET in a first-degree relative (relative risk 3.6).</p><p>The incidence of well-differentiated NETs has been rising over time in the United States and elsewhere [<a href="#rid4">4-7</a>]. As an example, in an analysis of 64,971 NETs reported to the SEER registry, the age-adjusted incidence rate for all NETs rose from 1.09 to 6.98 per 100,000 between 1973 and 2012 [<a href="#rid7">7</a>]. The increase is probably partly due to increased detection on radiographic imaging and endoscopy.</p><p class="headingAnchor" id="H3796865"><span class="h2">Distribution</span><span class="headingEndMark"> — </span>The distribution of NETs has shifted over time in the United States. In a report from the SEER database of 11,427 cases treated between 1973 and 1997, the majority were located in the gastrointestinal tract (55 percent) and bronchopulmonary system (30 percent) [<a href="#rid8">8</a>]. Within the gastrointestinal tract, most NETs arose in the small intestine (45 percent, most commonly in the ileum), followed by the rectum (20 percent), appendix (16 percent), colon (11 percent), and stomach (7 percent). However, since the implementation of screening colonoscopy (approximately in the year 2000), the proportion of patients diagnosed with rectal NETs has been greater than the proportion of those diagnosed with small intestinal NETs in 12 of 13 SEER registry reporting agencies [<a href="#rid9">9</a>]. The rising incidence of rectal NETs over time, and in all age groups, including 20 to 29 year olds, has been noted by others [<a href="#rid10">10</a>].</p><p>Distribution may differ in other geographic areas. As an example, colorectal NETs may be more frequent in the Asia/Pacific region as compared with Europe, where GINETs are more commonly found in the stomach and ileum [<a href="#rid11">11,12</a>]. An important point is that the SEER database may be inconsistent in recording tumors that are not considered "malignant" (ie, small gastric NETs that are encountered at endoscopy in patients with chronic atrophic gastritis). (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PATHOLOGY AND GRADING</span><span class="headingEndMark"> — </span>Well-differentiated NETs arising in the tubular gastrointestinal tract, lung, and genitourinary tract were initially referred to as "carcinoids" because they seemed morphologically different and clinically less aggressive than the more common gastrointestinal tract adenocarcinomas [<a href="#rid13">13</a>]. NETs arise from enterochromaffin (neuroendocrine) cells of the aerodigestive tract. The term enterochromaffin refers to the ability to stain with potassium chromate (chromaffin), a feature of cells that contain serotonin.</p><p>While most NETs are relatively slow-growing neoplasms, some behave aggressively. Histologic grade and differentiation correlate closely with clinical behavior. Grade refers to the proliferative activity of tumors, commonly measured by the mitotic rate (number of mitotic figures per 10 high-powered fields) or the Ki-67 index. In contrast, differentiation refers to the extent to which neoplastic cells resemble their non-neoplastic counterparts [<a href="#rid14">14</a>].</p><p>The World Health Organization (WHO) distinguishes two broad subgroups of neuroendocrine neoplasms affecting the digestive tract  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 3</a>) [<a href="#rid15">15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Well-differentiated NETs, which are further subdivided into low grade (G1), intermediate grade (G2), and high grade (G3) according to proliferative rate  (<a class="graphic graphic_table graphicRef122325" href="/d/graphic/122325.html" rel="external">table 3</a>). In general, clinical behavior of low/intermediate grade tumors is relatively indolent. However, it is important to note that metastatic tumors can transform over time to become much more aggressive. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p></p><p class="bulletIndent1">Intermediate-grade NETs arising in the lung (but not elsewhere) are referred to as atypical carcinoids. (See  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung  (<a class="graphic graphic_picture graphicRef74630" href="/d/graphic/74630.html" rel="external">picture 1</a>) [<a href="#rid16">16</a>]. They generally behave in a biologically aggressive fashion. (See  <a class="medical medical_review" href="/d/html/98796.html" rel="external">"High-grade gastroenteropancreatic neuroendocrine neoplasms"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It is important to distinguish between well-differentiated G3 NET (which are biologically similar to low and intermediate grade tumors), and poorly differentiated NEC. A more detailed discussion of the pathology and classification of NETs arising in the digestive tract is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/14247.html" rel="external">"Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system"</a>.)</p><p></p><p class="headingAnchor" id="H4"><span class="h1">EMBRYONIC CLASSIFICATION</span><span class="headingEndMark"> — </span>NETs arising in the tubular gastrointestinal tract, lung, and genitourinary tract have traditionally been classified based on their origin from the embryonic divisions (foregut, midgut, or hindgut) of the alimentary tract  (<a class="graphic graphic_figure graphicRef83185" href="/d/graphic/83185.html" rel="external">figure 1</a>) [<a href="#rid17">17</a>]. In general, midgut gastrointestinal tract NETs (distal small intestine and proximal colon) produce serotonin and other vasoactive substances that give rise to the typical carcinoid syndrome  (<a class="graphic graphic_table graphicRef56015" href="/d/graphic/56015.html" rel="external">table 4</a>). In contrast, tumors derived from the embryonic hindgut are rarely associated with a hormonal syndrome. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Pathophysiology'</a>.)</p><p>While this classification has some utility as a means of grouping together tumor sites according to their likelihood of producing a hormonal syndrome, it is increasingly evident that each specific primary site possesses its own unique clinical characteristics.</p><p class="headingAnchor" id="H7"><span class="h1">FOREGUT TUMORS</span><span class="headingEndMark"> — </span>The symptoms associated with foregut tumors vary with the site.</p><p class="headingAnchor" id="H8"><span class="h2">Stomach</span><span class="headingEndMark"> — </span>Gastric NETs are subdivided into three categories that have differing biologic behavior and prognoses [<a href="#rid18">18,19</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Type 1</span><span class="headingEndMark"> — </span>Type 1 tumors account for 70 to 80 percent of all gastric NETs [<a href="#rid19">19-21</a>]. They are associated with chronic atrophic gastritis and often pernicious anemia (65 percent in one series) [<a href="#rid19">19</a>]. The disease is more common in females [<a href="#rid22">22-24</a>]. (See  <a class="medical medical_review" href="/d/html/30.html" rel="external">"Metaplastic (chronic) atrophic gastritis"</a>.)</p><p>Endoscopically, the tumors are usually smaller than 1 cm, are often multiple, and may appear as polypoid lesions with a small central ulceration  (<a class="graphic graphic_picture graphicRef81095 graphicRef73158 graphicRef53130" href="/d/graphic/81095.html" rel="external">picture 2A-C</a>). The tumors are derived from enterochromaffin-like (ECL) cells.</p><p>The prevailing hypothesis is that ECL cells develop into NETs after chronic stimulation by the high gastrin levels that occur in patients with atrophic gastritis. This is supported by the observation that regression of gastric NETs can be achieved by antrectomy, which is occasionally recommended. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Stomach'</a>.)</p><p>Patients with gastric NETs related to chronic atrophic gastritis are usually diagnosed in their 60s or 70s during endoscopic evaluation for abdominal pain or anemia [<a href="#rid19">19</a>]. They are usually nonfunctioning tumors. These tumors are usually indolent and generally represent a benign condition. Metastases occur in less than 10 percent of tumors ≤2 cm but approximately 20 percent of larger tumors [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Type 2</span><span class="headingEndMark"> — </span>Type 2 gastric NETs occur in association with gastrinomas (Zollinger-Ellison syndrome), often in the setting of multiple endocrine neoplasia type 1 (MEN1). They account for approximately 5 percent of gastric NETs. Similar to the NETs that arise in the setting of atrophic gastritis, the tumors are thought to arise from ECL cells stimulated by elevated serum gastrin levels. The hypergastrinemia is produced by a gastrinoma in the pancreas or duodenum. (See  <a class="medical medical_review" href="/d/html/2026.html" rel="external">"Multiple endocrine neoplasia type 1: Management"</a> and  <a class="medical medical_review" href="/d/html/2584.html" rel="external">"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"</a>.)</p><p>Type 2 tumors behave similarly to type 1 tumors; they are frequently multifocal and usually indolent [<a href="#rid26">26</a>]. Management is addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Stomach'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Type 3</span><span class="headingEndMark"> — </span>Type 3 gastric NETs are known as sporadic NETs because they occur in the absence of atrophic gastritis, Zollinger-Ellison syndrome, or MEN1 syndrome. They account for 20 percent of gastric NETs and are the most aggressive; local or hepatic metastases are present in up to 65 percent of patients who come to resection [<a href="#rid18">18,26</a>]. Unlike type 1 and 2 tumors, the fasting serum gastrin is usually normal in patients with type 3 gastric NETs.</p><p>Type 3 tumors often contain a variety of endocrine cells, and they may be associated with atypical carcinoid syndrome  (<a class="graphic graphic_table graphicRef56015" href="/d/graphic/56015.html" rel="external">table 4</a>). (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Gastric NET variant syndrome'</a>.)</p><p class="headingAnchor" id="H3257545413"><span class="h3">Patients receiving PPI therapy</span><span class="headingEndMark"> — </span>A fourth type of gastric NET has been recently described as arising in the setting of chronic proton pump inhibitor (PPI) use, which is associated with elevated serum gastrin levels [<a href="#rid27">27</a>]. These tumors are often, but not always, solitary. Pathologically, there tends to be evidence of parietal and enterochromaffin cell hyperplasia without evidence of atrophic gastritis. Although these mucosal changes are suggestive of hypergastrinemia, there is no underlying gastrinoma.</p><p>Tumors arising in the setting of chronic PPI use appear to behave in a less malignant fashion than true-sporadic tumors [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Lung</span><span class="headingEndMark"> — </span>Well-differentiated lung NETs are classified among other pulmonary neuroendocrine neoplasms, such as small cell and large cell neuroendocrine lung cancer. (See  <a class="medical medical_review" href="/d/html/4603.html" rel="external">"Pathology of lung malignancies", section on 'Neuroendocrine tumors'</a>.)</p><p>Patients with lung NETs rarely develop carcinoid syndrome, even in the presence of liver metastases. They may have a variant carcinoid syndrome with flushes or sweats that are severe and prolonged, lasting hours to days. These flushes may be associated with disorientation, anxiety, and tremor. The clinical features of lung NETs are discussed separately. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Lung NET variant syndrome'</a> and  <a class="medical medical_review" href="/d/html/4883.html" rel="external">"Lung neuroendocrine (carcinoid) tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging", section on 'Clinical features'</a>.)</p><p class="headingAnchor" id="H13"><span class="h1">MIDGUT TUMORS</span></p><p class="headingAnchor" id="H14"><span class="h2">Jejunoileal small bowel tumors</span><span class="headingEndMark"> — </span>Small bowel NETs have increased in frequency in the last several decades, in part due to increased detection on endoscopy and imaging studies [<a href="#rid28">28</a>]. In the year 2000, NETs surpassed adenocarcinomas as the most common small bowel tumor reported to the National Cancer Database [<a href="#rid29">29</a>]. Patients usually present in their 60s or 70s. (See  <a class="medical medical_review" href="/d/html/2517.html" rel="external">"Epidemiology, clinical features, and types of small bowel neoplasms", section on 'Malignant tumors'</a>.)</p><p>Small bowel NETs are thought to arise from intraepithelial endocrine cells, in contrast to appendiceal NETs, which arise from subepithelial endocrine cells [<a href="#rid30">30</a>]. Small intestinal NETs are most commonly located in the ileum within 60 cm of the ileocecal valve; they may arise from a Meckel's diverticulum [<a href="#rid28">28,31-33</a>]. Approximately 25 percent of patients will have more than one small bowel NET at the time of discovery.</p><p>Some small bowel NETs are asymptomatic at presentation and are found incidentally [<a href="#rid34">34</a>]. Among symptomatic patients, abdominal pain is the most common initial symptom, occurring in approximately 40 percent [<a href="#rid35">35</a>]. The pain is usually vague and nonspecific, and may be incorrectly assumed to represent irritable bowel syndrome for years before the diagnosis is made. Intermittent obstruction occurs in 25 percent of small intestinal NETs [<a href="#rid35">35,36</a>]. Duodenal NETs may produce duodenal or biliary obstruction.</p><p>Abdominal pain may be due to intussusception, the mechanical effect of the tumor, or mesenteric ischemia. Obstruction may be caused by intussusception or intraluminal tumor bulk, but it often results from mesenteric kinking and distortion brought on by tumor invasion, lymph node metastases, and/or a secondary desmoplastic response  (<a class="graphic graphic_diagnosticimage graphicRef78186" href="/d/graphic/78186.html" rel="external">image 1</a>) [<a href="#rid37">37</a>]. The last produces a characteristic radiographic abnormality: a combination of abrupt angulation and a filling defect in the small bowel  (<a class="graphic graphic_diagnosticimage graphicRef60836" href="/d/graphic/60836.html" rel="external">image 2</a>).</p><p>Pain may also arise from ischemia that is due to local fibrosis or vascular compromise [<a href="#rid36">36</a>]. Vascular compromise may be secondary to large, bulky mesenteric nodal metastasis, mesenteric vascular invasion, and/or microvascular metastasis [<a href="#rid36">36</a>]. Possibly contributing to the ischemic process is the vasospastic effect of serotonin produced by the tumor.</p><p>Metastases to lymph nodes or the liver are common, even if the primary tumor is &lt;2 cm in size  (<a class="graphic graphic_table graphicRef82306" href="/d/graphic/82306.html" rel="external">table 5</a>) [<a href="#rid38">38,39</a>]. Carcinoid syndrome is present in the majority of patients who have a small bowel primary NET and liver metastases [<a href="#rid38">38,40-42</a>]. Staging, treatment, and prognosis of small bowel carcinoid NETs are addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Small intestine'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Appendix</span><span class="headingEndMark"> — </span>Well-differentiated NETs are the most common neoplasms in the appendix. In approximately 1 in 300 appendectomies, a NET is discovered incidentally, most often in the tip of the appendix. (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Terminology and classification'</a>.)</p><p>Appendiceal NETs are detected most commonly in the patients in their 40s or 50s, which most likely reflects the younger age of patients who undergo appendectomy. They are probably more common in females, although this association has in part been attributed to the greater frequency of incidental appendectomies in females who undergo pelvic surgery. (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Terminology and classification'</a>.)</p><p>The majority are submucosal and located in the distal one-third of the appendix, where they are unlikely to cause obstruction  (<a class="graphic graphic_picture graphicRef50408 graphicRef80087" href="/d/graphic/50408.html" rel="external">picture 3A-B</a>). As a result, most patients are asymptomatic. Symptoms are more likely with large tumors and in the rare patient with metastases beyond the regional lymph nodes. Approximately 10 percent of appendiceal NETs are located at the base of the appendix, where they can cause obstruction leading to appendicitis.</p><p>The likelihood of regional and distant metastases is related to tumor size but is much lower than for small intestinal NETs  (<a class="graphic graphic_table graphicRef82306" href="/d/graphic/82306.html" rel="external">table 5</a>). Features of carcinoid syndrome may be present in patients with tumors that have metastasized to the liver. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p>A rare type of appendiceal tumor, formerly referred to as "adenocarcinoid" or "goblet cell carcinoid," is now more appropriately termed "goblet cell adenocarcinoma" [<a href="#rid43">43</a>]. These cancers are staged and treated as epithelial tumors of the appendix and are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/119122.html" rel="external">"Epithelial tumors of the appendix", section on 'Goblet cell adenocarcinoma'</a>.)</p><p>The staging, prognosis, and treatment of appendiceal NETs are discussed separately. (See  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Staging and prognosis'</a> and  <a class="medical medical_review" href="/d/html/2527.html" rel="external">"Well-differentiated neuroendocrine tumors of the appendix", section on 'Treatment of localized disease'</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">HINDGUT TUMORS</span><span class="headingEndMark"> — </span>Hindgut NETs (transverse and descending colon, rectum) are usually nonsecretory and not associated with carcinoid syndrome, even when metastatic  (<a class="graphic graphic_table graphicRef56015" href="/d/graphic/56015.html" rel="external">table 4</a>). When symptoms do occur, they are the same as those of a colorectal adenocarcinoma: changes in bowel habits, obstruction, or bleeding. (See  <a class="medical medical_review" href="/d/html/2496.html" rel="external">"Clinical presentation, diagnosis, and staging of colorectal cancer", section on 'Clinical presentation'</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Colon</span><span class="headingEndMark"> — </span>Colonic NETs are usually detected in patients who are in their 70s during evaluation for diarrhea, abdominal pain, anorexia, or weight loss [<a href="#rid44">44,45</a>]. The incidence of functioning tumors is very low. Features of carcinoid syndrome were present in only 1 of 36 patients in one series from the Alberta Cancer Registry [<a href="#rid46">46</a>].</p><p>The majority of colonic NETs are located in the right colon, particularly in the cecum [<a href="#rid44">44,46,47</a>]. Most patients do not become symptomatic until the tumors are large. In two series, the average size of the tumors was approximately 5 cm at diagnosis [<a href="#rid44">44,47</a>], and approximately two-thirds were associated with local nodal, or distant metastasis  (<a class="graphic graphic_table graphicRef82306" href="/d/graphic/82306.html" rel="external">table 5</a>).</p><p>Staging, treatment, and prognosis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Colon'</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Rectum</span><span class="headingEndMark"> — </span>The vast majority of rectal NETs are asymptomatic and found incidentally on endoscopy that is performed for another reason [<a href="#rid45">45,48</a>]. They are most commonly diagnosed in patients in their 60s [<a href="#rid49">49</a>]. Uncommon manifestations include rectal bleeding, change in bowel habits, or pain; carcinoid syndrome is rare because most are nonsecretory.</p><p>The majority (75 to 85 percent) are localized at diagnosis [<a href="#rid45">45</a>]. However, size correlates closely with the likelihood of metastases. Tumors smaller than 1 cm are rarely metastatic [<a href="#rid25">25,50</a>], while approximately 6 percent of tumors between 1 and 1.9 cm, and 24 percent of those over 2 cm metastasize to the liver [<a href="#rid31">31,50-52</a>]. Other poor prognostic features include deep invasion (into the muscularis propria or deeper), lymphovascular invasion, and a high mitotic rate (≥2 per 50 high-power fields) [<a href="#rid52">52,53</a>].</p><p>Staging, prognosis, and treatment are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2615.html" rel="external">"Staging, treatment, and post-treatment surveillance of non-metastatic, well-differentiated gastrointestinal tract neuroendocrine (carcinoid) tumors", section on 'Rectum'</a>.)</p><p class="headingAnchor" id="H19"><span class="h2">Genitourinary</span><span class="headingEndMark"> — </span>NETs rarely arise in the genitourinary system; however, both renal and testicular primary tumors have been described in case reports and case series [<a href="#rid54">54-57</a>]. In addition to primary tumors, renal and testicular NETs may represent metastatic spread from another site [<a href="#rid57">57,58</a>]. These lesions commonly present as an abdominal or testicular mass, but some have manifestations of carcinoid syndrome. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">OVARY</span><span class="headingEndMark"> — </span>Ovarian NETs are rare neoplasms that may be primary or metastatic. Primary ovarian NETs are usually unilateral, localized to the ovary, and composed of gastrointestinal or respiratory epithelium; they often arise within a cystic teratoma or dermoid tumor [<a href="#rid59">59,60</a>]. (See  <a class="medical medical_review" href="/d/html/3236.html" rel="external">"Ovarian germ cell tumors: Pathology, epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p>The coexistence of an ovarian germ cell tumor may have prognostic implications. In one report, 189 of 329 primary ovarian NETs (57 percent) coexisted with cystic teratomas/dermoid tumors [<a href="#rid60">60</a>]. When compared with NETs without associated germ cell tumors, these NETs were significantly smaller (45 versus 90 mm), less likely to have liver metastases (2 versus 15 percent), and less likely to have carcinoid syndrome (14 versus 23 percent), and the five-year survival rates were modestly better (94 versus 84 percent).</p><p>Metastatic NETs to the ovaries occur most commonly in patients with intestinal primary tumors [<a href="#rid61">61</a>]. Unlike primary ovarian NETs, which are typically unilateral, metastatic NETs to the ovaries are usually bilateral, originate in the small intestine, and are associated with peritoneal carcinomatosis [<a href="#rid61">61</a>].</p><p>Rarely, ovarian NETs can produce carcinoid syndrome without hepatic metastases due to their direct drainage into the systemic circulation [<a href="#rid62">62</a>]. Some ovarian NETs that produce peptide YY, a gastrointestinal hormone responsible for decreased gut motility, have been associated with severe constipation [<a href="#rid63">63</a>]. (See  <a class="medical medical_review" href="/d/html/2595.html" rel="external">"Pancreatic polypeptide, peptide YY, and neuropeptide Y"</a>.)</p><p class="headingAnchor" id="H10901463"><span class="h1">OTHER RARE SITES</span><span class="headingEndMark"> — </span>Primary well-differentiated NETs have rarely been diagnosed at other sites, including the liver, gallbladder, cystic duct, thymus, and middle ear. While many patients present with liver-only disease, it is debatable whether some of these tumors are true liver primaries or represent metastases from an occult primary site. (See  <a class="medical medical_review" href="/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="headingAnchor" id="H1304714531"><span class="h1">METASTATIC TUMORS</span><span class="headingEndMark"> — </span>Regardless of primary site, NETs are characterized by a strong propensity to metastasize to the liver [<a href="#rid41">41</a>]. Patients with liver metastases may experience symptoms related to tumor burden (eg, pain, jaundice, early satiety) or hormonal symptoms (eg, flushing and diarrhea, the main symptoms of carcinoid syndrome). Even when extensive, metastatic well-differentiated NETs can often cause significant hepatomegaly without any abnormalities of liver function. (See  <a class="medical medical_review" href="/d/html/2614.html" rel="external">"Clinical features of carcinoid syndrome", section on 'Clinical features'</a>.)</p><p>Other common metastatic sites associated with small intestinal (midgut) NETs include the mesentery and peritoneum. Tumors in the root of the mesentery may be unresectable and lead to recurrent bowel obstruction or ischemia. Likewise, patients with peritoneal carcinomatosis may experience chronic obstruction, weight loss, and malnutrition [<a href="#rid40">40</a>].</p><p>Bone metastases are observed increasingly commonly in patients with metastatic NETs, particularly with the use of sensitive somatostatin-receptor-based imaging modalities, such as integrated positron emission tomography (PET)/computed tomography (CT) using <a class="drug drug_general" data-topicid="108440" href="/d/drug information/108440.html" rel="external">gallium Ga-68 DOTATATE</a> or gallium Ga-68 DOTATOC [<a href="#rid64">64</a>]. Other metastatic sites include the retroperitoneal lymph nodes, ovaries, breasts, supraclavicular lymph nodes, and retroorbital sites. (See  <a class="medical medical_review" href="/d/html/2194.html" rel="external">"Metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring", section on 'Somatostatin receptor-based imaging techniques'</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distribution</strong> – Well-differentiated neuroendocrine tumors (NETs) are rare neoplasms that can arise at several body sites. The majority originate in the gastrointestinal tract (55 percent) and lungs (30 percent); they rarely arise in the genitourinary tract. (See <a class="local">'Distribution'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classification and grading</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>NETs arise from enterochromaffin cells. They have traditionally been classified based on their origin from the embryonic divisions of the alimentary tract: the foregut (bronchial, stomach), midgut (small intestine, appendix, cecum), or hindgut (distal colon, rectum, genitourinary). (See <a class="local">'Embryonic classification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Histologically, NETs are classified based on histologic grade and differentiation. (See <a class="local">'Pathology and grading'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Well-differentiated NETs are further subdivided into low grade (G1), intermediate grade (G2), and high grade (G3) according to proliferative rate. In general, clinical behavior of low/intermediate NETs is relatively indolent.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Poorly differentiated neuroendocrine carcinomas are high-grade malignancies that resemble small cell or large cell neuroendocrine carcinoma of the lung. They generally behave in a biologically aggressive fashion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical behavior</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most well-differentiated NET are relatively slow growing. The metastatic potential of localized well-differentiated NETs correlates with tumor size, location, and histologic grade. Metastatic tumors can become much more aggressive over time.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical symptoms may be general, or they may correlate with the location of the tumor and be organ related. Symptoms of carcinoid syndrome (eg, flushing and diarrhea) typically occur in patients with metastatic NETs originating in the small bowel. (See <a class="local">'Midgut tumors'</a> above.)</p><p></p><p class="bulletIndent2">Rarely, carcinoid syndrome is observed in non-metastatic tumors that can release hormones directly into the systemic circulation (eg, lungs, ovaries). (See <a class="local">'Lung'</a> above and <a class="local">'Ovary'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gastric tumors are typically asymptomatic and they are subclassified into three types that have different clinical presentation and malignant potential. (See <a class="local">'Stomach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Small intestinal NETs often present with abdominal pain and/or intermittent obstruction. (See <a class="local">'Jejunoileal small bowel tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Appendiceal NETs are the most common neoplasm found in the appendix; they are most often discovered incidentally during appendectomy. (See <a class="local">'Appendix'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transverse colon, descending colon, and rectal NETs may present with changes in bowel habit, obstruction, or bleeding. However, the great majority of rectal NETs are discovered incidentally at the time of rectal examination or endoscopy. (See <a class="local">'Hindgut tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ovarian NETs may be primary or metastatic. Primary ovarian NETs are often associated with an ovarian germ cell tumor. (See <a class="local">'Ovary'</a> above.)</p><p></p><p class="headingAnchor" id="H2072777628"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editorial staff at UpToDate acknowledge Stephen Goldfinger, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.</a></li><li><a class="nounderline abstract_t">Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.</a></li><li><a class="nounderline abstract_t">Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92:2204.</a></li><li><a class="nounderline abstract_t">Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21:1794.</a></li><li><a class="nounderline abstract_t">Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013; 24:3040.</a></li><li><a class="nounderline abstract_t">Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer 2015; 121:589.</a></li><li><a class="nounderline abstract_t">Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol 2017; 3:1335.</a></li><li><a class="nounderline abstract_t">Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117.</a></li><li><a class="nounderline abstract_t">Taghavi S, Jayarajan SN, Powers BD, et al. Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis. Dis Colon Rectum 2013; 56:952.</a></li><li><a class="nounderline abstract_t">Montminy EM, Zhou M, Maniscalco L, et al. Contributions of Adenocarcinoma and Carcinoid Tumors to Early-Onset Colorectal Cancer Incidence Rates in the United States. Ann Intern Med 2021; 174:157.</a></li><li><a class="nounderline abstract_t">Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45:234.</a></li><li><a class="nounderline abstract_t">Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17:909.</a></li><li><a class="nounderline abstract_t">Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998; 352:799.</a></li><li><a class="nounderline abstract_t">Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.</a></li><li class="breakAll">Klimstra DS, Kloppell G, La Rosa S, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019. p.16.</li><li><a class="nounderline abstract_t">Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.</a></li><li><a class="nounderline abstract_t">WILLIAMS ED, SANDLER M. The classification of carcinoid tum ours. Lancet 1963; 1:238.</a></li><li><a class="nounderline abstract_t">Bordi C. Endocrine tumours of the stomach. Pathol Res Pract 1995; 191:373.</a></li><li><a class="nounderline abstract_t">Borch K, Ahrén B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64.</a></li><li><a class="nounderline abstract_t">Sculco D, Bilgrami S. Pernicious anemia and gastric carcinoid tumor: case report and review. Am J Gastroenterol 1997; 92:1378.</a></li><li><a class="nounderline abstract_t">Hirschowitz BI, Griffith J, Pellegrin D, et al. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102:1409.</a></li><li><a class="nounderline abstract_t">Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20:168.</a></li><li><a class="nounderline abstract_t">Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73:2053.</a></li><li><a class="nounderline abstract_t">Dakin GF, Warner RR, Pomp A, et al. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93:368.</a></li><li><a class="nounderline abstract_t">Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005; 103:1587.</a></li><li><a class="nounderline abstract_t">Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90:338.</a></li><li><a class="nounderline abstract_t">Rais R, Trikalinos NA, Liu J, Chatterjee D. Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use. Arch Pathol Lab Med 2022; 146:366.</a></li><li><a class="nounderline abstract_t">Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007; 102:1464.</a></li><li><a class="nounderline abstract_t">Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.</a></li><li><a class="nounderline abstract_t">Capella C, Heitz PU, Höfler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547.</a></li><li><a class="nounderline abstract_t">Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.</a></li><li><a class="nounderline abstract_t">Solcia E, Fiocca R, Rindi G, et al. Endocrine tumors of the small and large intestine. Pathol Res Pract 1995; 191:366.</a></li><li><a class="nounderline abstract_t">Wolff BG, Park JJ. Meckel's diverticulum, a "hot spot" for cancer. Ann Surg 2011; 253:231.</a></li><li><a class="nounderline abstract_t">Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.</a></li><li><a class="nounderline abstract_t">Saha S, Hoda S, Godfrey R, et al. Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J 1989; 82:1501.</a></li><li><a class="nounderline abstract_t">Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 1981; 90:720.</a></li><li><a class="nounderline abstract_t">Laskaratos FM, Rombouts K, Caplin M, et al. Neuroendocrine tumors and fibrosis: An unsolved mystery? Cancer 2017; 123:4770.</a></li><li><a class="nounderline abstract_t">Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79:1086.</a></li><li><a class="nounderline abstract_t">Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28:317.</a></li><li><a class="nounderline abstract_t">MOERTEL CG, SAUER WG, DOCKERTY MB, BAGGENSTOSS AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901.</a></li><li><a class="nounderline abstract_t">Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89:471.</a></li><li><a class="nounderline abstract_t">Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.</a></li><li class="breakAll">WHO Classification of Tumours of the Digestive System, 5th ed, WHO Classification of Tumours Editorial Board (Ed), IARC, 2019. Vol 1.</li><li><a class="nounderline abstract_t">Rosenberg JM, Welch JP. Carcinoid tumors of the colon. A study of 72 patients. Am J Surg 1985; 149:775.</a></li><li><a class="nounderline abstract_t">Caplin M, Sundin A, Nillson O, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95:88.</a></li><li><a class="nounderline abstract_t">Spread C, Berkel H, Jewell L, et al. Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994; 37:482.</a></li><li><a class="nounderline abstract_t">Ballantyne GH, Savoca PE, Flannery JT, et al. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer 1992; 69:2400.</a></li><li><a class="nounderline abstract_t">Jetmore AB, Ray JE, Gathright JB Jr, et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992; 35:717.</a></li><li><a class="nounderline abstract_t">Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813.</a></li><li><a class="nounderline abstract_t">Koura AN, Giacco GG, Curley SA, et al. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997; 79:1294.</a></li><li><a class="nounderline abstract_t">Mani S, Modlin IM, Ballantyne G, et al. Carcinoids of the rectum. J Am Coll Surg 1994; 179:231.</a></li><li><a class="nounderline abstract_t">Shields CJ, Tiret E, Winter DC, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 2010; 252:750.</a></li><li><a class="nounderline abstract_t">Fahy BN, Tang LH, Klimstra D, et al. Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment. Ann Surg Oncol 2007; 14:1735.</a></li><li><a class="nounderline abstract_t">Hansel DE, Epstein JI, Berbescu E, et al. Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol 2007; 31:1539.</a></li><li><a class="nounderline abstract_t">Shurtleff BT, Shvarts O, Rajfer J. Carcinoid tumor of the kidney: case report and review of the literature. Rev Urol 2005; 7:229.</a></li><li><a class="nounderline abstract_t">Zavala-Pompa A, Ro JY, el-Naggar A, et al. Primary carcinoid tumor of testis. Immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature. Cancer 1993; 72:1726.</a></li><li><a class="nounderline abstract_t">Stroosma OB, Delaere KP. Carcinoid tumours of the testis. BJU Int 2008; 101:1101.</a></li><li><a class="nounderline abstract_t">Tal R, Lask DM, Livne PM. Metastatic renal carcinoid: case report and review of the literature. Urology 2003; 61:838.</a></li><li><a class="nounderline abstract_t">Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol 1996; 61:259.</a></li><li><a class="nounderline abstract_t">Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases. J Exp Clin Cancer Res 2000; 19:271.</a></li><li><a class="nounderline abstract_t">Strosberg J, Nasir A, Cragun J, et al. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol 2007; 106:65.</a></li><li><a class="nounderline abstract_t">Pappa I, Peros G, Lappas C, et al. Management of ovarian carcinoid syndrome. Int J Gynaecol Obstet 2011; 115:205.</a></li><li><a class="nounderline abstract_t">Muller KE, Tafe LJ, Gonzalez JL, et al. Ovarian strumal carcinoid producing peptide YY associated with severe constipation: a case report and review of the literature. Int J Gynecol Pathol 2015; 34:30.</a></li><li><a class="nounderline abstract_t">Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009; 50:1214.</a></li></ol></div><div id="topicVersionRevision">Topic 2613 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080850" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18565894" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11596039" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20139156" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050954" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25312765" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28448665" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15213627" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Updated population-based review of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23838863" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Examining rectal carcinoids in the era of screening colonoscopy: a surveillance, epidemiology, and end results analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315473" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Contributions of Adenocarcinoma and Carcinoid Tumors to Early-Onset Colorectal Cancer Incidence Rates in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20058030" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20702725" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9737302" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Carcinoid tumour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664470" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18473355" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bronchopulmonary neuroendocrine tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14000847" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The classification of carcinoid tum ours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479354" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Endocrine tumours of the stomach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15973103" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9260813" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pernicious anemia and gastric carcinoid tumor: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1551550" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8661813" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156510" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16550587" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15742328" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872269" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34283890" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Enterochromaffin-like Cell Hyperplasia-Associated Gastric Neuroendocrine Tumors May Arise in the Setting of Proton Pump Inhibitor Use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17391319" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19106677" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7697211" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Revised classification of neuroendocrine tumours of the lung, pancreas and gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12569593" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A 5-decade analysis of 13,715 carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7479353" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Endocrine tumors of the small and large intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21217508" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Meckel's diverticulum, a "hot spot" for cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22262080" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2595419" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Carcinoid tumors of the gastrointestinal tract: a 44-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7281010" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112233" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Neuroendocrine tumors and fibrosis: An unsolved mystery?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9070484" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7879684" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Surgical management of gastrointestinal carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13771655" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Life history of the carcinoid tumor of the small intestine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19174605" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246527" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21246527" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2409828" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Carcinoid tumors of the colon. A study of 72 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261972" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8181412" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Colon carcinoid tumors. A population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568162" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1643994" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Rectal carcinoids: the most frequent carcinoid tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024720" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : An analysis of 8305 cases of carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083149" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8044398" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Carcinoids of the rectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21037430" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Carcinoid tumors of the rectum: a multi-institutional international collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17294074" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895755" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Renal carcinoid tumor: a clinicopathologic study of 21 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16985835" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Carcinoid tumor of the kidney: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7688660" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Primary carcinoid tumor of testis. Immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18190641" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Carcinoid tumours of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12670585" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Metastatic renal carcinoid: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8626144" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Primary ovarian carcinoid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11144518" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Carcinoids of the ovary: an analysis of 329 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17475313" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21872235" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Management of ovarian carcinoid syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25473750" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ovarian strumal carcinoid producing peptide YY associated with severe constipation: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19617343" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
